Contact information
Research groups
Rachael Drake-Brockman
Clinical Trials Coordinator
Rachael joined the Oxford Vaccine Group as a Clinical Trial Support Officer in November 2018. She advanced to the position of Clinical Trials Coordinator in October 2020 with the responsibility for managing the admin team and the coordination of admin tasks to support the smooth running of clinical trials.
Recent publications
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
-
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Flaxman A. et al, (2021), Lancet, 398, 981 - 990
-
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Barrett JR. et al, (2021), Nat Med, 27
-
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Ewer KJ. et al, (2021), Nat Med, 27
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Voysey M. et al, (2021), Lancet, 397, 881 - 891